# Strides Pharma Science share price today (Strides Pharma Science Ltd, NSE: STAR)

> Strides Pharma Science share price today: ₹1,037.30 at the NSE close on 3 November 2026, up 11.0% in a year. Strides Pharma Science (NSE: STAR) is worth ₹9,559 crore, trades at a P/E of 16.6 and has closed between ₹796.25 and ₹1,219.80 over the past 52 weeks. > Strides Pharma Science Ltd is reporting record margins. STAR · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/strides-pharma-science-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: ₹1,037.30 (+11.0% in a year)
- P/E: 16.6× (higher than 51% of the last 11 years)
- Revenue (Sep 2026): ₹1,430 Cr (+17.1% on a year ago)
- Profit (Sep 2026): ₹134 Cr (+1.5% on a year ago)
- Operating margin: 18.0% (−1.0 points on a year ago)
- ROCE: 18%, FY26
- Profit that came in as cash: 42%, last 3 years

The main question: profits are rising, but only 42% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Strides Pharma Science share price today? Strides Pharma Science Ltd's share price was ₹1,037.30 at the close on 3 November 2026. It has been rising for 179 weeks. That is 1.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹796 and ₹1,220, and at that close it sat 57% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 10 weeks in a row. Over the last 11 years the share price moved +108% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Strides Pharma Science this quarter? Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), indian funds and insurers (DIIs) raised their stake for 4 quarters in a row and foreign funds (FIIs) cut their stake for 3 quarters in a row. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹1,430 crore, +17.1% on a year earlier. Why: Revenue rose because sales outside the US grew fast and became bigger than US sales for the first time. Next results: check whether the products already launched start bringing in money in the second half. From the earnings call on 30 Oct 2026. 2. Indian funds and insurers (DIIs) raised their stake for 4 quarters in a row From 13% to 15.5% of the company by the September 2026 quarter. 3. Foreign funds (FIIs) cut their stake for 3 quarters in a row From 29.5% to 28% of the company by the September 2026 quarter. ## What are Strides Pharma Science's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Strides Pharma Science reported revenue of ₹1,430 crore, up 17.1% from ₹1,221 crore a year earlier, and a profit of ₹134 crore, up 1.5% from ₹132 crore. ### Strides Pharma Science results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹1,430 crore | ₹1,221 crore | +17.1% |
| Profit | ₹134 crore | ₹132 crore | +1.5% |
| Earnings per share | ₹14.20 | ₹13.84 | +2.6% |
| Operating margin | 18.0% | 19.0% | −1.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Strides Pharma Science's management discussed these results on a call held on 30 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Strides Pharma Science share price history? Strides Pharma Science closed at ₹1,037.30 on 3 November 2026, up 11.0% from ₹934.70 a year earlier (31 October 2025) and up 309.9% over five years. Its highest weekly close since March 2016 was ₹1,219.80 on 18 September 2026. ### Strides Pharma Science share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,014.80 | +2.2% |
| 1 month ago · 1 Oct 2026 | ₹1,084.80 | −4.4% |
| 6 months ago · 30 Apr 2026 | ₹1,036.80 | 0.0% |
| 1 year ago · 31 Oct 2025 | ₹934.70 | +11.0% |
| 3 years ago · 3 Nov 2023 | ₹221.88 | +367.5% |
| 5 years ago · 4 Nov 2021 | ₹253.09 | +309.9% |
| 10 years ago · 4 Nov 2016 | ₹496.60 | +108.9% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹498.86 | +107.9% |
| Highest weekly close since March 2016, also the 52-week high · 18 Sep 2026 | ₹1,219.80 | −15.0% |
| Lowest weekly close since March 2016 · 24 Mar 2023 | ₹128.75 | +705.7% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹796.25 | +30.3% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (564 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Strides Pharma Science? 3 Nov 2026: Strides Pharma Science closed at ₹1,037.30, up 2.2% on the week and down 4.4% on the month. 30 Oct 2026: Strides Pharma Science held its results call for July to September 2026. Management guided: US $375 million now planned beyond FY28 on shortage normalization and margin discipline. ### Earlier

- Results for July to September 2026: Revenue up 17.1% and profit up 1.5% on a year earlier. - 31 Jul 2026: ex-date for a dividend of ₹5 a share. ## What dividend does Strides Pharma Science pay? Strides Pharma Science paid ₹5 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.48% at the ₹1,037.30 close on 3 November 2026. The last was a dividend of ₹5 a share, ex-date 31 July 2026. ### Strides Pharma Science dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 31 Jul 2026 | ₹5 | Dividend | same day |
| 22 Jul 2025 | ₹4 | Dividend | same day |
| 9 Sep 2024 | ₹2.50 | Dividend | same day |
| 4 Aug 2023 | ₹1.50 | Dividend | same day |
| 5 Aug 2021 | ₹2.50 | Dividend | 6 Aug 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Strides Pharma Science Ltd paid out 8% of its profit as dividends in FY26, and it paid a dividend in 10 of its last 13 reported years. 2 of those years show a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Strides Pharma Science management say on the latest results call? On the call for July to September 2026, held on 30 October 2026, Strides Pharma Science's management guided: US $375 million now planned beyond FY28 on shortage normalization and margin discipline. > “We will not compromise on the profitability or quality of our business to chase revenues.”
> Badree, on the call for July to September 2026

### What management guided

- Ex-US above $375 million by FY28 on broad B2C and B2B momentum plus Sandoz scale. - 4-6 US launches in H2 with already launched products ramping to stronger second half. - Nasal spray approval expected January to March 2027 and controlled-substance patch launch Q3 with full FY28 benefit. - Gross margin within 58-60% band sustainable in H2 on cost-program traction and moderation. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/4495-30-Oct-2026.pdf). (From the call for July to September 2026, 30 October 2026.)

## What to watch in Strides Pharma Science's next results? When Strides Pharma Science reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Gross margin stays at flagged sustainable level in next print - per alternate sourcing traction and high-cost stock consumed. - What to check (from the call)
- Gross margin stays at flagged sustainable level in next print - per alternate sourcing traction and high-cost stock consumed. - US launch cluster delivers within guided range with already launched products ramping - per stronger second-half expectation. - Sandoz deal closes in guided quarter with second-half contribution starting - per pending antitrust clearance status. - Cash cycle reverses in next quarter with leverage stabilizing by year-end - per inventory normalization and second-half ramp. ## Which stock lists is Strides Pharma Science on? Strides Pharma Science is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 9556.981568113773](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 9556.981568113773](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Strides Pharma Science profitable? Strides Pharma Science Ltd earned ₹134 Cr of net profit in the Sep 2026 quarter, +1.5% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY26 profit was ₹575 Cr. Over 10 years profit has grown 19.7% a year on average. That is 9.4% of the quarter's revenue. The same quarter a year earlier earned ₹132 Cr. For the full year, FY26 profit was ₹575 Cr (−84.0% on the year before). Why profit moved: revenue changed +17.1% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +59.6% and revenue +11.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Strides Pharma Science make, and is it growing? Strides Pharma Science Ltd reported ₹1,430 Cr of revenue in the Sep 2026 quarter, +17.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 5.4% a year on average. The last full year, FY26, came in at ₹4,859 Cr. The last four reported quarters add to ₹5,213 Cr. FY26 revenue was ₹4,859 Cr, +6.4% on the year before. Recent pace: the last four quarters grew +11.2% on average, against 5.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.3%, against +10.5% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +53.6%, against −57.3% a year (accelerating). ## How much of every ₹100 of sales does Strides Pharma Science keep? Strides Pharma Science Ltd's operating margin was 18.0% in the Sep 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −17.0% and 19.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.3 percentage points on the year while gross margin changed −1.8 points. So the drop came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Strides Pharma Science's profit turning into cash? Over the last 3 years, 42% of Strides Pharma Science Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹703 Cr of operating cash against ₹575 Cr of profit. After ₹644 Cr of spending on assets, ₹59.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 42% of profit came in as cash: the cash cycle got 29 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 29 days longer. The next section looks at where the cash is stuck. ## Where does Strides Pharma Science's cash go? Strides Pharma Science Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 157 days in FY26, up from 128 days in FY21. It spent ₹694 Cr on assets over the last 3 years. Customers take 97 days to pay, and stock sits for 305 days on average. At FY26 sales of ₹4,859 Cr, each day of that cycle ties up about ₹13.3 Cr, so roughly ₹2,090 Cr is tied up in the business at any time. FY26: customers took 97 days to pay and stock sat for 305 days, about 10.0 months of sales sitting as stock, for a full cycle of 157 days, longer than FY21's 128. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 305 days. Customers pay about 97 days after that. Suppliers are paid at 244 days. Together that makes the 157-day cycle. Spending on assets: ₹694 Cr over the last 3 years, against ₹608 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹447 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Strides Pharma Science's P/E ratio, and how does it compare with its own history? Strides Pharma Science Ltd's P/E is 16.6×, in the middle of its own history: higher than 51% of past readings. Its usual P/E (the middle reading) is 16.3×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹66.92. Why the multiple is where it is: over the past year earnings per share moved −84.5% while the price moved +11.0%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +32.6% a year; about +63.6% a year came from earnings growth and about −31.0 percentage points from the multiple (the market paying less); over 10 years the price moved +7.6% a year; about +11.4% a year came from earnings growth and about −3.8 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 98% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Strides Pharma Science business getting better or worse? Strides Pharma Science Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE rising at 18.0%; each line tells part of the story. This is based on 9 quarters of 3 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Strides Pharma Science earn on its capital? Strides Pharma Science Ltd earned a ROCE of 18% in FY26. That is up from a low of −5% in FY22. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 11.8% net margin and 0.71× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 11.8% net margin × 0.71× asset turnover × 2.19× leverage (assets divided by equity) ≈ 18.3% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 98% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Strides Pharma Science have too much debt? Strides Pharma Science Ltd had ₹1,758 Cr of borrowings against ₹3,107 Cr of equity in FY26, so its debt is 0.57× its equity. Its operating profit is 5 times its interest bill. Over 5 years borrowings went from ₹2,348 Cr to ₹1,758 Cr. Over the last 3 of those years it spent ₹694 Cr on assets. The spending on assets is being paid for from cash, not new debt. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 98% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Strides Pharma Science shareholding pattern? Promoters raised their stake in Strides Pharma Science Ltd by 3.2 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 29.0% of the company. Domestic institutions moved −2.7 points over the same period, to 15.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +3.2 points over 8 quarters, to 29.0%; Domestic institutions: −2.7 points over 8 quarters, to 15.5%; Foreign institutions: −2.1 points over 8 quarters, to 28.0%. Why the owners changed: promoters drove it (+3.2 points), with the other side taken by domestic institutions (−2.7 points). They raised their stake step by step. ## How far is Strides Pharma Science from balance-sheet trouble? For Strides Pharma Science Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Strides Pharma Science rank in its industry? 55.3 out of 100, rank 18 of 44 in Pharma - Formulators, with 75% of the evidence available. Strides Pharma Science Ltd scores 55.3 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 18. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.1 + 13.3 + 11.3 + 9.6 = 55.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Strides Pharma Science compared with? Strides Pharma Science ranks 18 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 55.3 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. Strides Pharma Science Ltd this page STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 11.3% · Profit 53.6% · Operating margin change -1 points · 95% evidence Capital efficiency 13.3/25 · ROCE 18.3% · Operating margin 18% · 76% evidence Valuation 11.3/20 · P/E 17.1× · PEG n/a · 15% evidence Relative strength 9.6/20 · Lead over its industry -10.2% · Lead over NIFTY 500 12% · 1 year 14.3% · 100% evidence · 5 of 12 weeks ahead Exact sum: 21.1 + 13.3 + 11.3 + 9.6 = 55.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Strides Pharma Science in size? Strides Pharma Science is the 25th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Marksans Pharma, Corona Remedies and Akums Drugs & Pharmaceuticals. Just below it: Suven Life Sciences, Bliss GVS Pharma and FDC. ### Pharma - Formulators companies close in size

1. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) ₹13,876 crore
2. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) ₹13,147 crore
3. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) ₹11,517 crore
4. Strides Pharma Science Ltd ₹9,851 crore
5. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) ₹7,314 crore
6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) ₹6,888 crore
7. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) ₹6,138 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Blue Dart Express Ltd](https://www.sectoralpha.in/stocks/blue-dart-express-ltd) ₹9,897 crore · Logistics
2. [SignatureGlobal India Ltd](https://www.sectoralpha.in/stocks/signatureglobal-india-ltd) ₹9,883 crore · Realty - Construction & Contracting
3. Strides Pharma Science Ltd ₹9,851 crore
4. [India Cements Ltd](https://www.sectoralpha.in/stocks/india-cements-ltd) ₹9,672 crore · Cement
5. [Viyash Scientific Ltd](https://www.sectoralpha.in/stocks/viyash-scientific-ltd) ₹9,648 crore · Pharma - Animal

## What else do people ask about Strides Pharma Science? ### What is Strides Pharma Science's share price today? Strides Pharma Science Ltd's share price is ₹1,037.30, +11.0% over the past year. The whole company is worth ₹9,559 Cr on the market. In the last 52 weeks it traded between ₹796 to ₹1,220; today it is 57% of the way up from the low, 1.3% above its 200-day average (as of 3 November 2026). ### What were Strides Pharma Science's latest quarterly results? Strides Pharma Science Ltd reported revenue of ₹1,430 Cr and net profit of ₹134 Cr for the Sep 2026 quarter. Revenue rose 17.1% and profit rose 1.5% compared with a year earlier. Earnings per share were ₹14.20. The operating margin was 18.0%, 1.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Strides Pharma Science's market cap? Strides Pharma Science Ltd's market capitalisation is ₹9,559 Cr at a share price of ₹1,037.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Strides Pharma Science performing? Strides Pharma Science Ltd's share price has been rising for 179 weeks. In its latest quarter, revenue rose 17.1% and profit rose 1.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 10 weeks running (as of 3 November 2026). ### Will Strides Pharma Science's share price go up? This page does not forecast Strides Pharma Science Ltd's share price. What it shows instead: the share price is ₹1,037.30, and it has been rising for 179 weeks. Its P/E of 16.6× is higher than 51% of its own last 11 years (as of 3 November 2026). ### Who owns Strides Pharma Science? Promoters own 29.0% of Strides Pharma Science Ltd, foreign institutions 28.0%, domestic institutions 15.5% and the public 27.5% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 3.2 percentage points over 8 quarters (as of 3 November 2026). ### Where is Strides Pharma Science in its business cycle? Strides Pharma Science Ltd's FY26 operating margin was 19.0%, against a 13-year range of −17.0% to 19.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 18.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Strides Pharma Science story? The main question: profits are rising, but only 42% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Strides Pharma Science a stock worth studying right now? What the numbers show: Strides Pharma Science Ltd is reporting record margins. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Strides Pharma Science share price forecast for 2026? What management itself guided: US $375 million now planned beyond FY28 on shortage normalization and margin discipline. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.